Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA

• Published in: Gynecologic oncology Vol. 99; no. 1; pp. 153 - 159
• Main Authors: Berek, Jonathan S., Howe, Candace, Lagasse, Leo D., Hacker, Neville F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2005
• Subjects: Adult; Aged; Blood Loss, Surgical; Cervical cancer; Exenteration; Female; Genital Neoplasms, Female - epidemiology; Genital Neoplasms, Female - surgery; Humans; Middle Aged; Morbidity; Neoplasm Recurrence, Local - surgery; Pelvic Exenteration - adverse effects; Pelvic reconstruction; Reconstructive Surgical Procedures; Retrospective Studies; Survival Rate; Treatment Outcome; Exenteration; Cervical cancer; Pelvic reconstruction
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2005.05.034

To retrospectively assess the outcome of patients undergoing pelvic exenteration for recurrent or persistence gynecologic malignancy and the clinical features associated with outcome and survival. A review was conducted of patients who underwent pelvic exenteration over a 45-year period (1956–2001) at the UCLA Medical Center. Numerous clinical variables were analyzed, including time to relapse, type of exenteration and reconstructive operation, early (<60 days) and late (>60 days) morbidity, and survival. Variables were analyzed by chi-square and life-table analysis. Seventy-five patients (ages 26–74 years) had persistent cervical and vaginal (67) and uterine (8) cancer. Forty-six patients underwent total exenteration, 23 anterior, and 6 posterior. Sixty-nine (92%) patients underwent urinary diversion or neocystoplasty, 54 (72%) patients had a simultaneous neovagina created, and 43 of 52 (83%) patients who had a low colon resection had a primary reanastomosis. Twenty-nine patients died from recurrent malignancy, 28 were alive without disease, 11 were alive with disease, and 7 died from other causes at last follow-up. Survival for patients with cervical and vaginal cancer was 73% at 1 year, 57% at 3 years, and 54% at 5 years. Survival for patients with uterine cancer was 86% at 1 year, 62% at 3 and 5 years. The most frequent early morbidity was urinary tract infection, wound infection, and intestinal fistula; the most frequent late morbidity was urinary tract infection and intestinal obstruction. Pelvic exenteration in patients with recurrent cervical and vaginal malignancy is associated with a durable > 50% 5-year survival. Simultaneously performed pelvic reconstructive operations with a continent urinary diversion, the creation of a neovagina, and the reanastomosis of the colon with the formation of a J-pouch is now our standard; and these operations tend to improve the outcome of patients. Based on our initial experience, recurrent uterine corpus cancer in young women (< 55 years) should be included as an indication for the surgery.